22Nd Century Group Reports Third Quarter 2026 Financial Results
| Three Months Ended | ||||||||||||
| September 30, | Change | |||||||||||
| 2026 | 2025 | $ | % | |||||||||
| Revenues, net | $ | 4,759 | $ | 4,011 | 748 | 18.6 | ||||||
| Gross loss | $ | 446 | $ | (1,059 | ) | 1,505 | (142.1 | ) | ||||
| Operating loss | $ | (2,578 | ) | $ | (3,212 | ) | 634 | (19.7 | ) | |||
| Net loss from continuing operations | $ | (2,565 | ) | $ | (3,763 | ) | 1,198 | (31.8 | ) | |||
| Basic and diluted loss per common share from continuing operations | $ | (3.92 | ) | $ | (313.79 | ) | 309.87 | (98.8 | ) | |||
| Adjusted EBITDA (a) | $ | (2,206 | ) | $ | (2,886 | ) | 680 | 23.6 |
| Nine Months Ended | |||||||||||||
| September 30, | Change | ||||||||||||
| 2026 | 2025 | $ | % | ||||||||||
| Revenues, net | $ | 11,729 | $ | 14,050 | (2,321 | ) | (16.5 | ) | |||||
| Gross loss | $ | (481 | ) | $ | (2,303 | ) | 1,822 | (79.1 | ) | ||||
| Operating loss | $ | (8,906 | ) | $ | (8,763 | ) | (143 | ) | 1.6 | ||||
| Net loss from continuing operations | $ | (8,849 | ) | $ | (10,333 | ) | 1,484 | (14.4 | ) | ||||
| Basic and diluted loss per common share from continuing operations | $ | (29.47 | ) | $ | (2,290.62 | ) | 2,261.15 | (98.7 | ) | ||||
| Adjusted EBITDA (a) | $ | (8,302 | ) | $ | (7,844 | ) | (458 | ) | (5.8 | ) | |||
| (a) Adjusted EBITDA is a non-GAAP financial measure. Please see“Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures. |
Summary Product Line Results
(in thousands)
| Three Months Ended | |||||||||||
| September 30, | |||||||||||
| 2026 | 2025 | Change | |||||||||
| $ | Cartons | $ | Cartons | $ | Cartons | ||||||
| Contract manufacturing | |||||||||||
| Cigarettes | 3,930 | 131 | 2,520 | 345 | 1,410 | (214 | ) | ||||
| Filtered cigars | 674 | 80 | 1,282 | 168 | (608 | ) | (88 | ) | |||
| Other tobacco products | 123 | 12 | - | - | 123 | 12 | |||||
| Total contract manufacturing | 4,727 | 223 | 3,802 | 513 | 925 | (290 | ) | ||||
| VLN® | 32 | 1 | 209 | 4 | (177 | ) | (3 | ) | |||
| Total product line revenues | 4,759 | 224 | 4,011 | 517 | 748 | (293 | ) |
| Nine Months Ended | |||||||||||
| September 30, | |||||||||||
| 2026 | 2025 | Change | |||||||||
| $ | Cartons | $ | Cartons | $ | Cartons | ||||||
| Contract manufacturing | |||||||||||
| Cigarettes | 9,073 | 342 | 10,249 | 1,370 | (1,176 | ) | (1,028 | ) | |||
| Filtered cigars | 2,240 | 281 | 3,704 | 498 | (1,464 | ) | (217 | ) | |||
| Other tobacco products | 361 | 27 | 88 | 14 | 273 | 13 | |||||
| Total contract manufacturing | 11,674 | 650 | 14,041 | 1,882 | (2,367 | ) | (1,232 | ) | |||
| VLN® | 55 | 1 | 9 | 1 | 46 | - | |||||
| Total product line revenues | 11,729 | 651 | 14,050 | 1,883 | (2,321 | ) | (1,232 | ) |
About 22nd Century Group, Inc.
22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.
Our Technology is Tobacco
Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.
Our Products
We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption.
VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.
FDA Authorization and Scientific Foundation
VLN® low nicotine combustible cigarettes were authorized in December 2021, making them the first and still the only combustible cigarettes authorized by the U.S. Food and Drug Administration specifically to help reduce nicotine consumption.
Decades of independent clinical research and peer-reviewed studies-evaluated as part of the FDA's Modified Risk Tobacco Product (MRTP) authorization process-demonstrated that reducing nicotine content can decrease nicotine intake, increase quit attempts, and reduce overall exposure to nicotine.
FDA-authorized VLN® claims include:
- “95% less nicotine” “Helps reduce your nicotine consumption” “Greatly reduces your nicotine consumption” “Helps you smoke less”
VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.
Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
Learn more about VLN® at tryvln.com and pinnaclevln.com.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as“anticipate,”“believe,”“consider,”“continue,”“could,”“estimate,”“expect,”“explore,”“foresee,”“goal,”“guidance,”“intend,”“likely,”“may,”“plan,”“potential,”“predict,”“preliminary,”“probable,”“project,”“promising,”“seek,”“should,”“will,”“would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in“Risk Factors” in the Company's Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Report on Form 10-Q filed on May 7, 2026, August 14, 2026 and November 16, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
Notes regarding Non-GAAP Financial Information
In addition to the Company's reported results in accordance with generally accepted accounting principles in the United States of America (“GAAP”), the Company provides EBITDA and Adjusted EBITDA.
In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, master settlement agreement non-participating manufacturer settlement credits, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.
The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company's measurement of Adjusted EBITDA may not be comparable to those of other companies.
Investor Relations & Media Contact
Daniel Otto
Chief Financial Officer & Investor Relations
22nd Century Group
...
22nd CENTURY GROUP, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(amounts in thousands, except share and per-share data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,911 | $ | 7,149 | ||||
| Accounts receivable, net | 4,109 | 3,594 | ||||||
| Inventories | 4,357 | 4,326 | ||||||
| Prepaid expenses and other current assets | 1,887 | 2,562 | ||||||
| Total current assets | 14,264 | 17,631 | ||||||
| Property, plant and equipment, net | 2,808 | 2,440 | ||||||
| Operating lease right-of-use assets, net | 605 | 728 | ||||||
| Intangible assets, net | 5,638 | 6,224 | ||||||
| Other assets | 42 | - | ||||||
| Total assets | $ | 23,357 | $ | 27,023 | ||||
| LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Notes and loans payable-current | $ | 405 | $ | 204 | ||||
| Operating lease obligations | 180 | 168 | ||||||
| Accounts payable | 821 | 1,000 | ||||||
| Accrued expenses and other current liabilities | 789 | 836 | ||||||
| Accrued excise taxes and fees | 3,058 | 3,343 | ||||||
| Contract liabilities | 1,037 | 1,721 | ||||||
| Total current liabilities | 6,290 | 7,272 | ||||||
| Long-term liabilities: | ||||||||
| Notes and loans payable | 416 | 504 | ||||||
| Operating lease obligations | 464 | 601 | ||||||
| Other long-term liabilities | 111 | 154 | ||||||
| Total liabilities | 7,281 | 8,531 | ||||||
| Mezzanine equity: | ||||||||
| Series A convertible preferred shares, $0.00001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2026 and 9,650 at December 31, 2025, respectively | - | 2,734 | ||||||
| Total mezzanine equity | - | 2,734 | ||||||
| Shareholders' equity: | ||||||||
| Series B convertible preferred shares, $0.00001 par value; 10,000,000 shares authorized, 8,505 shares issued and outstanding at September 30, 2026 and 0 at December 31, 2025, respectively | - | - | ||||||
| Common stock, $.00001 par value, 500,000,000 shares authorized, 20,032 shares issued and outstanding at September 30, 2026 and 391 at December 31, 2025, respectively | - | - | ||||||
| Capital in excess of par value | 424,402 | 414,683 | ||||||
| Accumulated deficit | (408,326 | ) | (398,925 | ) | ||||
| Total shareholders' equity | 16,076 | 15,758 | ||||||
| Total liabilities, mezzanine equity and shareholders' equity | $ | 23,357 | $ | 27,023 |
22nd CENTURY GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(amounts in thousands, except share and per-share data)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues, net | $ | 4,759 | $ | 4,011 | $ | 11,729 | $ | 14,050 | ||||||||
| Cost of goods sold | 1,655 | 2,557 | 5,201 | 8,304 | ||||||||||||
| Excise taxes and fees on products | 2,658 | 2,513 | 7,009 | 8,049 | ||||||||||||
| Gross profit (loss) | 446 | (1,059 | ) | (481 | ) | (2,303 | ) | |||||||||
| Operating expenses: | ||||||||||||||||
| Sales, general and administrative | 2,451 | 1,849 | 7,272 | 5,766 | ||||||||||||
| Research and development | 233 | 193 | 813 | 583 | ||||||||||||
| Other operating expense, net | 339 | 111 | 339 | 111 | ||||||||||||
| Total operating expenses | 3,023 | 2,153 | 8,424 | 6,460 | ||||||||||||
| Operating loss from continuing operations | (2,577 | ) | (3,212 | ) | (8,905 | ) | (8,763 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Other expense | - | (33 | ) | - | (207 | ) | ||||||||||
| Interest income | 30 | 16 | 104 | 46 | ||||||||||||
| Interest expense | (17 | ) | (534 | ) | (47 | ) | (1,443 | ) | ||||||||
| Total other income (expense), net | 13 | (551 | ) | 57 | (1,604 | ) | ||||||||||
| Loss from continuing operations before income taxes | (2,564 | ) | (3,763 | ) | (8,848 | ) | (10,367 | ) | ||||||||
| (Benefit) provision for income taxes | - | - | - | (34 | ) | |||||||||||
| Net loss from continuing operations | $ | (2,564 | ) | $ | (3,763 | ) | $ | (8,848 | ) | $ | (10,333 | ) | ||||
| Discontinued operations: | ||||||||||||||||
| (Loss) income from discontinued operations before income taxes | $ | (229 | ) | $ | 9,252 | $ | (552 | ) | $ | 8,087 | ||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net (loss) income from discontinued operations | $ | (229 | ) | $ | 9,252 | $ | (552 | ) | $ | 8,087 | ||||||
| Net (loss) income | $ | (2,793 | ) | $ | 5,489 | $ | (9,400 | ) | $ | (2,246 | ) | |||||
| Comprehensive (loss) income | $ | (2,793 | ) | $ | 5,489 | $ | (9,400 | ) | $ | (2,246 | ) | |||||
| Net (loss) income | $ | (2,793 | ) | $ | 5,489 | $ | (9,400 | ) | $ | (2,246 | ) | |||||
| Deemed dividends | - | - | (18,134 | ) | - | |||||||||||
| Dividend for redemption of Series A Convertible Preferred Stock | - | - | (6,916 | ) | - | |||||||||||
| Dividend for redemption of Series B Convertible Preferred Stock | - | - | (870 | ) | - | |||||||||||
| Net (loss) income available to common shareholders | $ | (2,793 | ) | $ | 5,489 | $ | (35,320 | ) | $ | (2,246 | ) | |||||
| Basic and diluted loss per share: | ||||||||||||||||
| Basic and diluted loss per common share from continuing operations | $ | (227.49 | ) | $ | (19,701.57 | ) | $ | (1,719.39 | ) | $ | (147,614.29 | ) | ||||
| Basic and diluted (loss) income per common share from discontinued operations | $ | (20.32 | ) | $ | 48,439.79 | $ | (107.27 | ) | $ | 115,528.57 | ||||||
| Basic and diluted (loss) income available to common shareholders per common share | $ | (247.80 | ) | $ | 28,738.22 | $ | (6,863.58 | ) | $ | (32,085.71 | ) | |||||
| Weighted average shares outstanding - basic and diluted | 11,271 | 191 | 5,146 | 70 |
Table A – Reconciliations of Non-GAAP Measures
(dollars in thousands, except share and per-share data)
Below is a table containing information relating to the Company's Net loss, EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2026 and 2025, including a reconciliation of these Non-GAAP measures for such periods.
| Three Months Ended | ||||||||||||
| September 30, | ||||||||||||
| Amounts in thousands ($000's) | ||||||||||||
| except share and per share data | ||||||||||||
| (UNAUDITED) | ||||||||||||
| $ Change | ||||||||||||
| 2026 | 2025 | fav / (unfav) 1 | ||||||||||
| Net loss from continuing operations | $ | (2,564 | ) | $ | (3,763 | ) | $ | 1,199 | ||||
| Interest (income)/expense, net | (13 | ) | 518 | (531 | ) | |||||||
| Provision (benefit) for income taxes | - | - | - | |||||||||
| Amortization and depreciation | 207 | 234 | (27 | ) | ||||||||
| EBITDA | $ | (2,370 | ) | $ | (3,011 | ) | $ | 641 | ||||
| Adjustments: | ||||||||||||
| Change in fair value of warrant liabilities | - | 33 | (33 | ) | ||||||||
| Excise taxes and fees on products - MSA NPM settlement credits | (550 | ) | - | (550 | ) | |||||||
| Impairment of intangible assets | 339 | - | 339 | |||||||||
| Equity-based employee compensation expense | 375 | 92 | 283 | |||||||||
| Adjusted EBITDA | $ | (2,206 | ) | $ | (2,886 | ) | $ | 680 | ||||
| Adjusted EBITDA loss per common share | $ | (195.70 | ) | $ | (15,146.14 | ) | $ | 14,950.44 | ||||
| Weighted average common shares outstanding - basic and diluted | 11,271 | 191 |
| Nine Months Ended | ||||||||||||
| September 30, | ||||||||||||
| Amounts in thousands ($000's) | ||||||||||||
| except share and per share data | ||||||||||||
| (UNAUDITED) | ||||||||||||
| $ Change | ||||||||||||
| 2026 | 2025 | fav / (unfav) 1 | ||||||||||
| Net loss from continuing operations | $ | (8,848 | ) | $ | (10,333 | ) | $ | 1,485 | ||||
| Interest (income)/expense, net | (58 | ) | 1,397 | (1,455 | ) | |||||||
| Provision (benefit) for income taxes | - | (34 | ) | 34 | ||||||||
| Amortization and depreciation | 623 | 694 | (71 | ) | ||||||||
| EBITDA | $ | (8,283 | ) | $ | (8,276 | ) | $ | (7 | ) | |||
| Adjustments: | ||||||||||||
| Change in fair value of warrant liabilities | - | 207 | (207 | ) | ||||||||
| Excise taxes and fees on products - MSA NPM settlement credits | (1,242 | ) | - | (1,242 | ) | |||||||
| Impairment of intangible assets | 339 | - | 339 | |||||||||
| Equity-based employee compensation expense | 886 | 225 | 661 | |||||||||
| Adjusted EBITDA | $ | (8,300 | ) | $ | (7,844 | ) | $ | (456 | ) | |||
| Adjusted EBITDA loss per common share | $ | (1,612.99 | ) | $ | (112,263.68 | ) | $ | 110,650.69 | ||||
| Weighted average common shares outstanding - basic and diluted | 5,146 | 70 |
1Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment